Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
omega-3 fatty acids (Massachusetts General Hospital, f21f9f)
- Development stage
- Phase 1
- Lead developer
- Massachusetts General Hospital
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Omega-3 fatty acids, specifically formulations high in eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are being investigated by researchers at Massachusetts General Hospital for the treatment of pediatric bipolar spectrum disorder. These polyunsaturated fatty acids are thought to exert therapeutic effects by supporting neuronal health, modulating neurotransmission, and reducing neuroinflammation. Clinical research led by Dr. Janet Wozniak has evaluated omega-3 fatty acids both as a monotherapy and as an adjunctive treatment (e.g., with inositol or aripiprazole) in children and adolescents. The treatment aims to alleviate symptoms of mania and depression by stabilizing neuronal membranes and influencing intracellular signaling pathways.
- Brand names
- LovazaOmacorVascepa
- Other names
- n-3 polyunsaturated fatty acidsn3 polyunsaturated fatty acidsn 3 polyunsaturated fatty acidsn3PUFAn-3PUFAn 3PUFAfish oilEPADHAeicosapentaenoic aciddocosahexaenoic acid
02
Targets
FFAR4 (Free fatty acid receptor 4)PPARG (Peroxisome proliferator-activated receptor gamma)PKC (Protein kinase C family)
Beyond the preview
Go deeper on omega-3 fatty acids (Massachusetts General Hospital, f21f9f).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on omega-3 fatty acids (Massachusetts General Hospital, f21f9f).